Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study

Catherine Quantin (1, 2, 3, 4, 5) , C. Yamdjieu Ngadeu (2, 3) , Jonathan Cottenet (2, 3) , Sylvie Escolano (1) , Sonia Bechraoui-Quantin (2, 3) , Patrick Rozenberg (1, 6) , Pascale Tubert-Bitter (1) , Jean-Bernard Gouyon (7)

1 CESP - Centre de recherche en épidémiologie et santé des populations
2 DIM - Service Biostatistiques et Informatique Médicale (CHU de Dijon)
3 UBFC - Université Bourgogne Franche-Comté [COMUE]
4 CIC-P803 - Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie
5 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
6 Service de gynécologie et obstétrique [CHI Poissy-Saint Germain]
7 CEPOI - Centre d'Études Périnatales de l'Océan Indien

Objective: To assess the risk of preterm birth associated with nonsteroidal anti-inflammatory drugs (NSAIDs), focusing on early exposure in the period from conception to 22 weeks of gestation (WG). Design: National population-based retrospective cohort study. Setting: The French National Health Insurance Database that includes hospital discharge data and health claims data. Population: Singleton pregnancies (2012–2014) with a live birth occurring after 22WG from women between 15 and 45 years old and insured the year before the first day of gestation and during pregnancy were included. We excluded pregnancies for which anti-inflammatory medications were dispensed after 22WG. Methods: The association between exposure and risk of preterm birth was evaluated with GEE models, adjusting on a large number of covariables, socio-demographic variables, maternal comorbidities, prescription drugs and pregnancy complications. Main outcome measures: Prematurity, defined as a birth that occurred before 37WG. Results: Among our 1 598 330 singleton pregnancies, early exposure to non-selective NSAIDs was associated with a significantly increased risk of preterm birth, regardless of the severity of prematurity: adjusted odds ratio (aOR) = 1.76 (95% CI 1.54–2.00) for extreme prematurity (95% CI 22–27WG), 1.28 (95% CI 1.17–1.40) for moderate prematurity (28–31WG) and 1.08 (95% CI 1.05–1.11) for late prematurity (32–36WG), with non-overlapping confidence intervals. We identified five NSAIDs for which the risk of premature birth was significantly increased: ketoprofen, flurbiprofen, nabumetone, etodolac and indomethacin: for the latter, aOR = 1.92 (95% CI 1.37–2.70) with aOR = 9.33 (95% CI 3.75–23.22) for extreme prematurity. Conclusion: Overall, non-selective NSAID use (delivered outside hospitals) during the first 22WG was found to be associated with an increased risk of prematurity. However, the association differs among NSAIDs. Tweetable abstract: French study for which early exposure to non-selective NSAIDs was associated with increased risk of prematurity.

Mots clés: Early exposure; French National Health Insurance Database; non-steroidal anti-inflammatory drugs; risk of prematurity

Domaines: Gynécologie et obstétrique; Pharmacologie; Santé publique et épidémiologie

Catherine Quantin, C. Yamdjieu Ngadeu, Jonathan Cottenet, Sylvie Escolano, Sonia Bechraoui-Quantin, et al.. Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study. BJOG: An International Journal of Obstetrics and Gynaecology, 2021, 128 (10), pp.1575-1584. ⟨10.1111/1471-0528.16670⟩. ⟨hal-03401796⟩